SEARCH?

Search anything and hit enter

The activation of the endocannabinoid system’s CB2 receptors elicits significant neuroprotection that could help inhibit Parkinson’s disease.

Findings in a recent animal trial suggest that cannabinoids could be beneficial for treating Parkinson’s disease. The study, published in Frontiers in Neuroscience, found that the activation of the endocannabinoid system’s cannabinoid type two receptors (CB2) stimulates anti-inflammatory and antioxidant effects that protect against neurodegeneration.

Parkinson’s disease is a chronic, progressive disorder of the nervous system. The disease is associated with a loss of neurons that produce dopamine, a chemical responsible for sending messages to the brain related to movement. The current therapies for Parkinson’s disease focus on managing the disorder’s symptoms and remain inadequate at inhibiting the progression of the disease.

In the study, researchers from United Arab Emirates University used six to seven month old rats that had been induced with Parkinson’s disease. One group of rats had 50 mg/kg of β-caryophyllene (BCP), an established CB2 receptor agonist, administered to them daily for 4 weeks. All the brains of the rats were then examined after the four-week period.

The investigators discovered that β-caryophyllene effectively upregulated the expression of CB2 receptors compared to the control group. This activation of the receptor significantly reduced the loss of dopamine-producing neurons. It also significantly reduced malondialdehyde, a recognized oxidative stress biomarker, and protected from a drop in the antioxidant glutathione compared to control group animals.

The activation of CB2 receptors also augmented the activity of a pair of antioxidant enzymes – superoxide dismutase and catalase. It also inhibited increased nitrate levels in the midbrain and alleviated the Parkinson’s disease-induced glial cell activation in the striatum.

The upregulation of CB2 receptors was also found to be associated with an improvement in the level of proinflammatory cytokines in the midbrain and inflammatory mediators NF-κB, COX-2, and iNOS.

“Taken together, the abrogation of the protective effects… demonstrates the CB2 receptor-dependent mechanism of BCP and the findings can be extrapolated to the neuroprotective properties of CB2 agonism in PD,” the researchers conclude.

The findings suggest that cannabinoids derived from cannabis, which interact with cannabinoid receptors, could be beneficial for Parkinson’s disease. Previous studies have found evidence that cannabinoids offer neuroprotective effects that are beneficial for Parkinson’s.

“In recent years, the cannabinoid receptors, specifically activating CB2 receptors, appear to represent a novel therapeutic target for neurodegenerative diseases, including [Parkinson’s disease], because of their role in counteracting oxidative stress and inflammation,” the study reads. “The CB2 receptors have recently emerged as a potential anti-inflammatory target, to break the self-sustaining cycle of neuroinflammation and preserve neuronal homeostasis, and survival in neurodegenerative disorders.”

Enter your email below

Follow us on social networks

DIGITAL CONTENT WRITER

DIGITAL CONTENT WRITER

This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Food and Drug Admistration (FDA) Disclosure

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the medicalmarijuanainc.com website. Links to any informational websites are provided solely as a service to our users.

The link provides additional information that may be useful or interesting and has no aliation to the promotion, sale and distribution of Medical Marijuana Inc. products. The link does not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.

* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.